Evaluation of Ciclo 21® Effect (Levonorgestrel + Ethinyl Estradiol) Compared to Nordette®.

Inclusion Criteria: 1. Comply with all study procedures, sign, initial and date back, of their own free will, the IC; 2. Women aged between 18 and 35 years, regardless of race and class; 3. Make use of safe non-hormonal method of contraception such as tubal ligation, non-hormonal IUDs or condoms, or be hysterectomised or be vasectomized sexual partner; 4. Examination of Beta-HCG negative; 5. with regular menstrual cycles every 24 to 32 days, at least the last three months; 6. present normal Pap test (current or during the past 02 years); 7. Present or vaginal examination found that the changes do not interfere in the study; 8. present levels of FSH, LH, estradiol and TT for the normal menstrual cycle, as well as normal transvaginal sonographic reports. Exclusion Criteria: 1. Provide a contraindication to the use of steroids; 2. Use regular or prediction of drugs that interfere with the metabolism of the investigational products, such as antibiotics, anticonvulsants, anticoagulants and hypoglycemic drugs; 3. smokers or have stopped smoking less than 12 months; 4. Diabetic; 5. Toxic-dependent; 6. BMI \<18 and\> 25; 7. have made use of topical or systemic sex hormone for at least two months before the start of the study; 8. Background and personal or family history of thrombosis or bleeding disorders or vascular disorders or cardiovascular disease; 9. Laboratory tests, gynecological ultrasound or changed, the medical criteria; 10. Individuals with allergies or rheumatic diseases for which is indicated the use of cortico-steroid medication; 11. carry any endocrine changes, especially pituitary and gonadal and / or who are advised to use hormones; 12. with lesions or abnormalities suspected or confirmed in the gonads. 13. personal or family history of breast cancer or other hormone-dependent breast pathology; 14. with hypertension or diabetes mellitus (for drug interactions between the COC and hypoglycemic agents and antihypertensives); a) History of nausea with oral use of COCs; p) Any condition that may interfere with the discretion of the investigator in the study data as well as being the measurement of the study be deleterious to the patient.